UCB NORDIC A/S: Financial statements 2022
CVR: 26688949
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 61,499,000 and a net result of DKK 4,004,000 compared with DKK 3,016,000 the year before. That is an increase of 1.6% compared with the year before. Equity in the 2022 report amounted to DKK 15,118,000. The solvency ratio was 26.2%. The company had 40 employees in the financial year.
- Gross Profit
- DKK 61,499,000
- Profit/Loss
- DKK 4,004,000
- Equity
- DKK 15,118,000
- Total Assets
- DKK 57,654,000
- Employees
- 40
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 61.5M | 4M | 15.1M | 40 |
| 2021 | - | 60.5M | 3M | 14.1M | 40 |
| 2020 | - | 46.2M | 3.7M | 11.1M | 31 |
| 2019 | - | 39.5M | 3.6M | 10.6M | 26 |
| 2018 | - | 34.6M | 3.3M | 10.3M | 24 |
Official annual report
Keep an eye on UCB NORDIC A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
UCB NORDIC A/S has published its annual report for 2021. Gross profit came to DKK 60,527,000, and the net result was DKK 3,016,000.
As of June 1, 2022, Mari-Ann Retz is registered as director of UCB NORDIC A/S.
As of June 1, 2022, Henrik Dramer Bøgebjerg Hansen has stepped down as director of UCB NORDIC A/S.
As of May 20, 2022, Ana Isabel Infante Gonzalez De La Aleja has joined the board of directors of UCB NORDIC A/S.
As of May 20, 2022, Ilaria Villa has left the board of directors of UCB NORDIC A/S.
About UCB NORDIC A/S
UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.